This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.
CADTH. Gabapentin for adults with neuropathic pain: a review of the clinical evidence and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response. 2014
Indirect evidence suggests similar short-term pain relief with gabapentin compared with pregabalin, tricyclic antidepressants and serotonin norepinephrine reuptake inhibitors in patients with painful diabetic neuropathy, postherpetic neuralgia and fibromyalgia. There is lower quality evidence of misuse of gabapentin and pregabalin but the prevalence of misuse is unknown.
Subject indexing assigned by CRD
Cyclohexanecarboxylic Acids; Neuralgia; gamma-Aminobutyric Acids
Country of organisation
An English language summary is available.
Address for correspondence
Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: email@example.com
Date abstract record published